Vestal Point Capital’s Ascendis Pharma A/S ASND Stock Holding History

Vestal Point Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$100M	Hold	375,000	–	–	2.34%	15
2026 Q1	$85.8M	Buy	375,000 +200,000	+114%	+$44.8M	2.4%	11
2025 Q4	$37.3M	Sell	175,000 -425,000	-71%	-$87.8M	1.27%	26
2025 Q3	$119M	Buy	600,000 +400,000	+200%	+$74.6M	5.39%	1
2025 Q2	$34.5M	Buy	200,000 +49,858	+33%	+$8.12M	1.82%	19
2025 Q1	$23.4M	Sell	150,142 -369,858	-71%	-$52.8M	1.67%	21
2024 Q4	$71.6M	Buy	520,000 +270,000	+108%	+$35.5M	4.24%	4
2024 Q3	$37.3M	Sell	250,000 -500,000	-67%	-$67.5M	2.83%	11
2024 Q2	$102M	Buy	750,000 +225,000	+43%	+$30.6M	7.63%	3
2024 Q1	$79.4M	Sell	525,000 -100,000	-16%	-$14.3M	6.56%	4
2023 Q4	$78.7M	Buy	+625,000	New	+$62.3M	8.34%	3

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vestal Point Capital's ASND Position: Q2 2026 in Review

Vestal Point Capital held its Ascendis Pharma A/S (ASND) position steady in Q2 2026 at 375,000 shares worth $100M. The position accounts for 2.34% of the portfolio, ranked #15.

Vestal Point Capital first reported a position in ASND in Q4 2023 and has held it in 11 quarters since. The position peaked at $119M in Q3 2025. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Vestal Point Capital held 375,000 shares of Ascendis Pharma A/S worth $100M as of Q2 2026.
Vestal Point Capital left its Ascendis Pharma A/S share count unchanged in Q2 2026.
Ascendis Pharma A/S made up 2.34% of Vestal Point Capital's portfolio in Q2 2026, its #15 holding.
Vestal Point Capital first reported a position in Ascendis Pharma A/S in Q4 2023 and has held it in 11 quarters since.
Vestal Point Capital's Ascendis Pharma A/S position peaked at $119M in Q3 2025.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.